Functional and structural basis of E. coli enolase inhibition by SF2312: A mimic of the carbanion intermediate

Many years ago, the natural secondary metabolite SF2312, produced by the actinomycete Micromonospora, was reported to display broad spectrum antibacterial properties against both Gram-positive and Gram-negative bacteria. Recent studies have revealed that SF2312, a natural phosphonic acid, functions...

Full description

Saved in:
Bibliographic Details
Main Authors: Krucinska, Jolanta, Lombardo, Michael N., Erlandsen, Heidi, Hazeen, Akram, Duay, Searle S., Pattis, Jason G., Robinson, Victoria L., May, Eric R., Wright, Dennis L.
Format: text
Published: Animo Repository 2019
Subjects:
Online Access:https://animorepository.dlsu.edu.ph/faculty_research/11299
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: De La Salle University
Description
Summary:Many years ago, the natural secondary metabolite SF2312, produced by the actinomycete Micromonospora, was reported to display broad spectrum antibacterial properties against both Gram-positive and Gram-negative bacteria. Recent studies have revealed that SF2312, a natural phosphonic acid, functions as a potent inhibitor of human enolase. The mechanism of SF2312 inhibition of bacterial enolase and its role in bacterial growth and reproduction, however, have remained elusive. In this work, we detail a structural analysis of E. coli enolase bound to both SF2312 and its oxidized imide-form. Our studies support a model in which SF2312 acts as an analog of a high energy intermediate formed during the catalytic process. Biochemical, biophysical, computational and kinetic characterization of these compounds confirm that altering features characteristic of a putative carbanion (enolate) intermediate significantly reduces the potency of enzyme inhibition. When SF2312 is combined with fosfomycin in the presence of glucose-6 phosphate, significant synergy is observed. This suggests the two agents could be used as a potent combination, targeting distinct cellular mechanism for the treatment of bacterial infections. Together, our studies rationalize the structure-activity relationships for these phosphonates and validate enolase as a promising target for antibiotic discovery.